88 results
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for melanoma antigens to induce an immune response.The secondary objective is to show clinical response.
Primary: 1 to test the safety and feasibility of autologous MSC therapy in HLA-DR mismatched patients with SCR in the renal biopsy 4 weeks after renal transplantation.Secondary1 To assess histologic changes before and after MSC treatment.2 To…
To test the safety and feasibility of intravenous administration of autologous BM-MSC after one-sided LVRS and prior to a second LVRS procedure for patients with end-stage pulmonary emphysema and to compare with historic lung function data of a…
We expect to finalize the current phase I study by the May 2008 demonstrating that injection of tumor lysate-pulsed autologous DCs injected in patients with MM after chemotherapy is safe and well tolerated with induction of immune responses. New…
This is an exploratory study, consisting of two parts. In part I dose escalation is performed and the primary objective is the safety of different doses of TLR-DC and Trimix DC. In part II Trimix DC vaccination will be compared with TLR-DC…
The main objective is assessment of safety and feasibility of intravenous administration of autologous, in vitro expanded, mesenchymal stem cells in patients with pulmonary arterial hypertension due to systemic sclerosis. The secondary objective is…
To determine the efficacy and the safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
The objective of the present trial is to investigate the safety of an allogenic tumor cell lysate loaded onto autologuous dendritic cells (AlloDen) in patients with malignant mesothelioma (MM). Heretoo we will perform a phase I study with a…
To show immunologic efficacy of tumor-peptide loaded natural DC in mCRPC patients. Further we will demonstrate that natural DC vaccinations are safe, feasible and clinically effective. Also the therapy effect on quality of life will be studied.
This is an interventional study and the primary objective is the immunogenicity of combined pDC and myDC vaccination. The secondary objectives are the biodistribution, the safety, quality of life and overall survival.
To improve the steady hematopoiesis post-ASCT by infusing the autologous transplant directly in the bone marrow compartment.(protocol page 6)
The objective of the study is to ascertain whether the high effect sizes obtained in the previous studies can be explained according to our working hypothesis, i.e. whether the intervention with Urocell is associated with a structural regeneration…
The objective of this study is to prove that a single injection of PRP in the COE decreases the pain and duration of the condition in patients with chronic lateral epicondylitis compared to injection with lidocaine and corticosteroids.The specific…
Primary objective: To confirm the safety of the use of Urocell as a treatment for stress incontinence due to intrinsic sphinctre deficiency.Secondary ojectives: - To score the quelity of life with a standardized questionnaire and to score the level…
Primary: To test the safety and feasibility of autologous MSC therapy in patients with refractory Crohn*s Disease.Secondary:1 To evaluate clinical response in patients with refractory CD upon MSC infusion.2 To assess endoscopic- and histologic…
Objectives: 1. The primary objective is to evaluate the safety and immune modulation of TIL plus IFN* in epithelial ovarian cancer (EOC) patients and to determine the optimal dose of IFN* that can be given in combination with chemotherapy.2.…
This is an exploratory study and the primary objective is the immunogenicity and feasibility of combined chemotherapy-DC vaccination. The secondary objectives are the toxicity and clinical efficacy. This study will provide important data on the…
The study will evaluate the injection of AMDC for Urinary Sphincter Repair (USR) compared to a placebo dose, with the hypothesis that one or two treatments of AMDC is statistically superior to placebo at 12 months following the initial treatment.
The primary objective is to show superiority of treatment with DCVAC/PCa in addition to Standard of Care chemotherapy (docetaxel plus prednisone) over placebo in addition to Standard of Care chemotherapy (docetaxel plus prednisone) in men with mCRPC…
To demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells in addition to state of the art treatment is safe and reduces allcause mortality in patients with reduced left ventricular ejection fraction (…